Lamotrigine is widely used as a mood stabilizer for bipolar disorder, even though it was originally developed as an anti-seizure medication. The FDA approved it specifically for maintenance treatment of bipolar I disorder, meaning its job is to prevent future mood episodes rather than treat one that’s already happening. It’s particularly effective at keeping depressive episodes from coming back, which makes it unusual among mood stabilizers.
What Lamotrigine Is Approved to Treat
The FDA approval is narrow but important: lamotrigine is indicated for maintenance treatment of bipolar I disorder, specifically to delay the return of mood episodes including depression, mania, hypomania, and mixed episodes. The key word is “delay.” It’s a preventive tool, not a rescue medication.
What it’s not approved for is treating acute mania or mixed episodes. Large clinical trials tested lamotrigine for active manic episodes and found no benefit over placebo. So if you’re in the middle of a manic episode, lamotrigine won’t help bring you down. Its value shows up over months, keeping your mood from swinging back into crisis after you’ve already been stabilized with other treatments.
Canadian treatment guidelines (CANMAT/ISBD) list lamotrigine as a first-line option for acute bipolar depression alongside lithium, quetiapine, and lurasidone. This first-line status reflects strong clinical confidence in the drug despite its formal classification as an anticonvulsant rather than a traditional mood stabilizer.
Stronger Against Depression Than Mania
Lamotrigine’s standout feature is how well it prevents depressive episodes compared to manic ones. An 18-month clinical trial comparing lamotrigine, lithium, and placebo in bipolar I patients illustrates this clearly. Both lamotrigine and lithium outperformed placebo overall, but they each excelled in different directions.
For depression prevention, lamotrigine was the clear winner. At the one-year mark, 57% of patients on lamotrigine remained free of depressive episodes, compared to 46% on lithium and 45% on placebo. Lithium barely beat placebo for depression, while lamotrigine pulled significantly ahead.
For mania prevention, the pattern reversed. Lithium kept 86% of patients free of manic or hypomanic episodes at one year, versus 77% for lamotrigine and 72% for placebo. Lithium was statistically superior to placebo for preventing mania; lamotrigine was not.
This has led researchers to describe lamotrigine as a “mirror image” of lithium. Lithium prevents highs more than lows. Lamotrigine prevents lows more than highs. That distinction matters enormously if your bipolar disorder leans heavily toward depressive episodes, which is the case for many people with bipolar I and especially bipolar II. A Cochrane review did find a 33% reduction in the likelihood of recurrent mania with lamotrigine, suggesting it offers some protection on both sides, just much more on the depressive end.
How It Works in the Brain
Lamotrigine calms overactive brain signaling through two main pathways. First, it acts on voltage-gated ion channels to reduce excessive neuronal firing. Rather than dampening all brain activity, it selectively targets neurons that are firing at abnormally high rates, which may be what makes it effective for mood instability without causing heavy sedation.
Second, it reduces the release of glutamate, the brain’s primary excitatory chemical messenger. Too much glutamate activity is linked to mood dysregulation, and both lamotrigine and lithium share this glutamate-lowering effect. This overlap may help explain why both drugs work as mood stabilizers despite being chemically unrelated.
The Slow Start: Why Titration Takes Weeks
If you’ve been prescribed lamotrigine, the first thing you’ll notice is how gradually the dose increases. For bipolar disorder, the standard starting dose is just 25 mg daily (or 25 mg every other day if you’re also taking valproate). Over the course of six to seven weeks, the dose is slowly increased to a target of 200 mg daily. This cautious approach exists for a specific reason: reducing the risk of a serious skin reaction.
Starting too high or increasing too fast raises the chance of developing a rash, including in rare cases a severe condition called Stevens-Johnson syndrome, which causes painful blistering of the skin and mucous membranes. In adults, serious rash requiring hospitalization occurs in about 0.3% of patients, and the rate of possible Stevens-Johnson syndrome is around 0.1%. The risk is higher in children under 16, at roughly 0.5% for Stevens-Johnson syndrome and 1.0% for serious rash overall.
Taking valproate at the same time increases rash risk, which is why the starting dose drops even lower for that combination. Exceeding the recommended dose at any stage of the ramp-up also raises risk. This is one medication where patience with the slow buildup genuinely matters for safety.
What to Expect on Lamotrigine
Because of the gradual titration, you won’t reach a therapeutic dose for roughly six weeks. That means lamotrigine isn’t a quick fix. It’s a long-term strategy. Many people are started on another medication to stabilize an acute mood episode, with lamotrigine added as the maintenance plan to keep things stable going forward.
Compared to many other medications used in bipolar disorder, lamotrigine has a relatively mild side effect profile. It doesn’t typically cause the weight gain associated with some atypical antipsychotics, and it doesn’t require the blood level monitoring that lithium does. These practical advantages are a big part of why it’s so commonly prescribed for long-term use, even though its formal drug classification remains “anticonvulsant” rather than “mood stabilizer.”
For people whose bipolar disorder involves frequent or severe depressive episodes, lamotrigine fills a gap that few other medications cover as effectively. Most traditional mood stabilizers and antipsychotics do a better job against mania than depression. Lamotrigine does the opposite, making it a uniquely valuable option in the bipolar treatment landscape.